Phaseline

Companies › Sparrow Pharmaceuticals

Sparrow Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Genitourinary, Metabolic and endocrine; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
clofutriben
11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) inhibitor
HSD11B1Phase 2Type 2 Diabetes; Moderate Renal ImpairmentDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07227922clofutribenPhase 1Moderate Renal ImpairmentGenitourinaryApr 2026
NCT07296484clofutribenPhase 2Type 2 DiabetesMetabolic and endocrineDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

HSD11B1 (1)

Companies with the same targets

Merck & Co. (MSD)

Companies built like this

Vifor Pharma Maze Therapeutics Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Housey Healthcare ULC

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.